Versions Compared

Old Version 5

changes.mady.by.user Erin Muhlbradt

Saved on

compared with

New Version 6

changes.mady.by.user Erin Muhlbradt

Saved on

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

  • Date

 

Attendees

Goals

  • PGx and Oncology Cross-team Meeting to discuss outstanding PGx change requests and additional items

Discussion items

TimeItemWhoNotes
30min1.5hr

PGx Change Requests - including MRD Minimal Residual Disease　Characterization of the Tumor: Primary, Metastatic, etc. (BSTEST row 11)　

Erin/Joyce
PFTEST row 13, 14

    • - Keep as a BSTEST. EVS to come up with an appropriate TEST and definition.

 PGx Change Requests - including MRD Minimal Residual Disease (PF row 7)   

  • See PGx P30 working document -

    • PFTEST row 7 - minimal residual disease

30min Characterization of the Tumor: Primary, Metastatic, etc.   

Action items

  •  

    • - Do not add as new PFTEST. Keep in RS. Use REFID to link PF data to RS.

    • PFTEST row 13, 14 - These tests would be used with the MRD terminology in RS. Team agrees to add Clone Frequency. Team to discuss 'Myeloma cells/Leukocytes' on next call.

Team agreed one more call was required on . Next Call items to discuss:

BSTEST Row 11

PFTEST row 13, 14

 

Action items

  •  

    Erin Muhlbradt to send NCCN and Bruggerman MRD papers to PGx team

  •  Erin Muhlbradt to draft TEST name and definition for new BSTEST term on row 11 and PFTEST row 13, 14.
  •  Melanie Paules to send out PGx invite to Oncology team for next meeting on 2017-02-27
  •